Latest Period
Q4 2025
Security Snapshot
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) Institutional Ownership
CUSIP: 98420X103
13F Institutional Holders and Ownership History from Q1 2019 to Q4 2025
Institutions Reporting
3
Shares (Excl. Options)
3,507,120
Price
$4.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- XFOR on Nasdaq
- Shares outstanding
- 7,938,059
- Price per share
- $4.00
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 3,507,120
- Total reported value
- $14,028,434
- % of total 13F portfolios
- 0%
- Share change
- +1,000,028
- Value change
- +$4,000,064
- Number of holders
- 3
- Price from insider filings
- $4.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share is tracked under CUSIP 98420X103.
- 3 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 2 to 3 between Q3 2025 and Q4 2025.
- Reported value moved from $8,574,256 to $14,028,434.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 3 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 98420X103?
CUSIP 98420X103 identifies XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98420X103:
Significant Owners of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 4.8% | $1,558,172 | 8,200,903 | The Vanguard Group | 31 Dec 2024 | |||
| ORBIMED ADVISORS LLC | 1.7% | $25,640 | 134,947 | ORBIMED ADVISORS LLC | 30 Jun 2025 |
As of 31 Dec 2025, 3 institutional investors reported holding 3,507,120 shares of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR). This represents 44% of the company’s total 7,938,059 outstanding shares.
Top 3 Institutional Shareholders
The largest institutional shareholders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 41% | 3,233,743 | +45% | 0.66% | $12,934,972 |
| ACORN CAPITAL ADVISORS, LLC | 3.4% | 273,349 | 0% | 0.37% | $1,093,398 |
| RMG Wealth Management LLC | 0% | 28 | 0% | $64 |
Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 3,507,120 | $14,028,434 | +$4,000,064 | $4.00 | 3 |
| 2025 Q3 | 2,507,092 | $8,574,256 | +$6,340,007 | $3.42 | 2 |
| 2025 Q2 | 653,289 | $1,241,249 | -$59,123,616 | $1.90 | 2 |
| 2025 Q1 | 98,484,813 | $23,301,713 | -$1,452,474 | $0.24 | 91 |
| 2024 Q4 | 99,822,228 | $73,237,480 | -$4,976,749 | $0.73 | 89 |
| 2024 Q3 | 100,589,647 | $67,319,848 | -$551,327 | $0.67 | 98 |
| 2024 Q2 | 101,516,641 | $58,880,322 | -$4,474,635 | $0.58 | 97 |
| 2024 Q1 | 102,998,180 | $143,153,751 | +$10,326,109 | $1.39 | 96 |
| 2023 Q4 | 96,800,089 | $81,168,367 | -$18,734,277 | $0.84 | 92 |
| 2023 Q3 | 112,423,967 | $122,551,525 | -$3,809,593 | $1.09 | 91 |
| 2023 Q2 | 112,930,152 | $219,074,939 | +$103,525,068 | $1.94 | 96 |
| 2023 Q1 | 60,979,055 | $53,052,409 | +$698,212 | $0.87 | 56 |
| 2022 Q4 | 60,622,175 | $60,205,215 | +$20,545,513 | $0.99 | 52 |
| 2022 Q3 | 39,133,898 | $66,911,740 | +$39,611,313 | $1.71 | 54 |
| 2022 Q2 | 16,046,519 | $15,520,101 | -$680,561 | $0.96 | 44 |
| 2022 Q1 | 16,343,188 | $28,602,538 | -$2,230,268 | $1.75 | 52 |
| 2021 Q4 | 17,568,471 | $40,229,950 | -$2,286,455 | $2.29 | 49 |
| 2021 Q3 | 16,206,198 | $85,726,624 | -$2,862,733 | $5.29 | 48 |
| 2021 Q2 | 16,587,201 | $107,773,003 | +$971,565 | $6.50 | 58 |
| 2021 Q1 | 16,126,888 | $138,720,293 | +$48,924,159 | $8.61 | 59 |
| 2020 Q4 | 10,477,783 | $67,370,946 | +$1,560,507 | $6.43 | 53 |
| 2020 Q3 | 10,231,522 | $69,268,392 | -$5,283,243 | $6.77 | 50 |
| 2020 Q2 | 10,703,549 | $99,748,639 | -$2,349,709 | $9.32 | 54 |
| 2020 Q1 | 11,262,165 | $112,618,520 | +$1,382,834 | $10.00 | 49 |
| 2019 Q4 | 11,047,629 | $118,207,922 | +$34,786,028 | $10.70 | 53 |
| 2019 Q3 | 7,738,772 | $98,353,473 | +$1,731,349 | $12.71 | 49 |
| 2019 Q2 | 7,594,683 | $113,920,545 | +$87,071,950 | $15.00 | 43 |
| 2019 Q1 | 1,788,795 | $31,139,000 | +$31,139,000 | $17.41 | 29 |